NEX2US Newsletter Issue 09 | March 2023
Industry member
Cell, Tissue and Gene Therapy Products
Chinese Proprietary Medicines
Controlled drugs
Cosmetic products
Health supplements
Homeopathic medicines
Medical devices
Psychotropic substances and poisons
Therapeutic Products
Traditional medicines
14 March 2023
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Topics
Awards and Recognition
HSA won five Public Service Transformation (PST) Awards 2021/2022
Regulatory Updates and Process Enhancements
Therapeutic Products (TP) - Enabling regulatory efficiency and industry self-help
Medical Devices (MD) - Publication of Regulatory Guidelines for Laboratory Developed Tests (LDTs)
Complementary Health Products - Launch of Voluntary Notification System for Health Supplements and Traditional Medicines
International and Bilateral Collaborations
HSA Singapore the First National Regulatory Authority Awarded the Highest Recognition for an Advanced Medicines Regulatory System by the World Health Organization
Publication of the Access Consortium Statement on GMP Inspections Reliance and Recognition
Collaboration under the Access Consortium to enable faster access to treatment
ASEAN Pharmaceutical Regulatory Policy and ASEAN Pharmaceutical Regulatory Framework
HSA recognised by Australia’s Therapeutic Goods Administration (TGA) as a Comparable Overseas Regulator for medical devices
HSA included in Hong Kong’s list of reference countries for registration of new chemical or biological entity
News and Engagements
Complementary Health Products (CHP) Industry Training Workshop
Webinar on Dental Laboratory Regulatory Requirements in Singapore
Click on the link below to download the issue in pdf:
Subscribe to stay up to date with HSA news and regulatory updates.
